The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications.…

Novartis

Supreme Court urged to weigh in on six-month biosimilar delays

Top of 2017's pharma heap? Pfizer, Novartis, Roche—and 7 drugs headed for biosim attack

With $496M CNS sale, Novartis joins the herd of pharmas casting off tired meds